- Home
- PRSU vs PHAT Comparison
PRSU vs PHAT Comparison
Compare PRSU & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSU
- PHAT
- Stock Information
- Founded
- PRSU 1926
- PHAT 2018
- Country
- PRSU United States
- PHAT United States
- Employees
- PRSU N/A
- PHAT N/A
- Industry
- PRSU Business Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- PRSU Consumer Discretionary
- PHAT Health Care
- Exchange
- PRSU Nasdaq
- PHAT Nasdaq
- Market Cap
- PRSU 770.3M
- PHAT 727.5M
- IPO Year
- PRSU N/A
- PHAT 2019
- Fundamental
- Price
- PRSU $29.26
- PHAT $8.85
- Analyst Decision
- PRSU Strong Buy
- PHAT Strong Buy
- Analyst Count
- PRSU 3
- PHAT 5
- Target Price
- PRSU $29.67
- PHAT $16.40
- AVG Volume (30 Days)
- PRSU 284.1K
- PHAT 4.9M
- Earning Date
- PRSU 08-15-2025
- PHAT 08-07-2025
- Dividend Yield
- PRSU N/A
- PHAT N/A
- EPS Growth
- PRSU N/A
- PHAT N/A
- EPS
- PRSU 11.68
- PHAT N/A
- Revenue
- PRSU $366,836,000.00
- PHAT $81,859,000.00
- Revenue This Year
- PRSU $13.61
- PHAT $195.45
- Revenue Next Year
- PRSU $6.64
- PHAT $106.76
- P/E Ratio
- PRSU $2.50
- PHAT N/A
- Revenue Growth
- PRSU 189.47
- PHAT 3055.70
- 52 Week Low
- PRSU $26.66
- PHAT $2.21
- 52 Week High
- PRSU $47.49
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- PRSU N/A
- PHAT 56.80
- Support Level
- PRSU N/A
- PHAT $9.25
- Resistance Level
- PRSU N/A
- PHAT $10.13
- Average True Range (ATR)
- PRSU 0.00
- PHAT 0.95
- MACD
- PRSU 0.00
- PHAT -0.23
- Stochastic Oscillator
- PRSU 0.00
- PHAT 8.99
About PRSU Pursuit Attractions and Hospitality Inc. Common Stock
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.